Lipid accumulation product is related to metabolic syndrome in women with polycystic ovary syndrome

Experimental and Clinical Endocrinology and Diabetes

Volumn 121, Issue 2, 2013, Pages 115-118

  Xiang, S ^a   Hua, F ^a   Chen, L ^a   Tang, Y ^a   Jiang, X ^a   Liu, Z ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

lipid accumulation product; metabolic syndrome; polycystic ovary syndrome

Indexed keywords

ADULT; ANTHROPOMETRY; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; LIPID ACCUMULATION PRODUCT; LIPID STORAGE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OVARY POLYCYSTIC DISEASE; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; CHINA; CROSS-SECTIONAL STUDIES; EARLY DIAGNOSIS; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; OBESITY, ABDOMINAL; POLYCYSTIC OVARY SYNDROME; PREVALENCE; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TRIGLYCERIDES; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 84873960458     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0032-1333261     Document Type: Article

References (25)

1. Azziz R., Woods K. S., Reyna R. et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab: 2004; 89 2745 2749 (Pubitemid 38766360)
2. Ehrmann D. A. Polycystic ovary syndrome. N Engl J Med: 2005; 352 1223 1236
3. Homburg R. Polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol: 2008; 22 261 274 (Pubitemid 351297553)
4. Dunaif A., Xia J., Book C. B. et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest: 1995; 96 801 810
5. Gambineri A., Pelusi C., Vicennati V. et al. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord: 2002; 26 883 896 (Pubitemid 34756169)
6. Lo J. C., Feigenbaum S. L., Yang J. et al. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab: 2006; 91 1357 1363
7. Coviello A. D., Legro R. S., Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab: 2006; 91 492 497 (Pubitemid 43236914)
8. Ford E. S. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis: 2004; 173 309 314 (Pubitemid 38469801)
9. Rossi B., Sukalich S., Droz J. et al. Prevalence of metabolic syndrome and related characteristics in obese adolescents with and without polycystic ovary syndrome. J Clin Endocrinol Metab: 2008; 93 4780 4786
10. Kahn H. S. The "lipid accumulation producto" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord: 2005; 5 26
11. Kahn H. S. The lipid accumulation product is better than BMI for identifying diabetes: a population-based comparison. Diabetes Care: 2006; 29 151 153 (Pubitemid 44033451)
12. Wehr E., Gruber H. J., Giuliani A. et al. The lipid accumulation product is associated with impaired glucose tolerance in PCOS women. J Clin Endocrinol Metab: 2011; 96 E986 E990
13. Taverna M. J., Martinez-Larrad M. T., Frechtel G. D. et al. Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population. Eur J Endocrinol: 2011; 164 559 567
14. Tellechea M. L., Aranguren F., Martinez-Larrad M. T. et al. Ability of lipid accumulation product to identify metabolic syndrome in healthy men from Buenos Aires. Diabetes Care: 2009; 32 e85
15. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril: 2004; 81 19 25
16. Cussons A. J., Watts G. F., Burke V. et al. Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod: 2008; 23 2352 2358
17. Cheung L. P., Ma R. C., Lam P. M. et al. Cardiovascular risks and metabolic syndrome in Hong Kong Chinese women with polycystic ovary syndrome. Hum Reprod: 2008; 23 1431 1438 (Pubitemid 351770573)
18. Verit F. F. The prevalence of metabolic syndrome in clomiphene citrate resistant polycystic ovary syndrome. Gynecol Endocrinol: 2012; 28 365 369
19. Bhattacharya S. M. Prevalence of metabolic syndrome in women with polycystic ovary syndrome, using two proposed definitions. Gynecol Endocrinol: 2010; 26 516 520
20. Ni R. M., Mo Y., Chen X. et al. Low prevalence of the metabolic syndrome but high occurrence of various metabolic disorders in Chinese women with polycystic ovary syndrome. Eur J Endocrinol: 2009; 161 411 418
21. Oh J. Y., Sung Y. A., Lee H. J. et al. Optimal waist circumference for prediction of metabolic syndrome in young Korean women with polycystic ovary syndrome. Obesity (Silver Spring): 2010; 18 593 597
22. Despres J. P., Lemieux I., Bergeron J. et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol: 2008; 28 1039 1049
23. Wild S., Pierpoint T., McKeigue P. et al. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf): 2000; 52 595 600 (Pubitemid 30337085)
24. Wiltgen D., Benedetto I. G., Mastella L. S. et al. Lipid accumulation product index: a reliable marker of cardiovascular risk in polycystic ovary syndrome. Hum Reprod: 2009; 24 1726 1731
25. Wang F., Wu S., Song Y. et al. Waist circumference, body mass index and waist to hip ratio for prediction of the metabolic syndrome in Chinese. Nutr Metab Cardiovasc Dis: 2009; 19 542 547